Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 13Breast Neoplasms 12Colorectal Neoplasms 11Ovarian Neoplasms 10Recurrence 9Neoplasms 9Small Cell Lung Carcinoma 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma 5Multiple Myeloma 4Lymphoma, Follicular 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Mesothelioma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Kidney Neoplasms 3

Interventions

Gemcitabine 31Cisplatin 21pembrolizumab 8Fluorouracil 6Oxaliplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Taxes 4Albumin-Bound Paclitaxel 4pemigatinib 3infigratinib 3atezolizumab 3Specimen Handling 3Radiosurgery 3Platinum 3Magnetic Resonance Spectroscopy 3Leucovorin 3Carboplatin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2trametinib 2olaparib 2ivosidenib 2derazantinib 2cobimetinib 2Trastuzumab 2Radiotherapy 2Panitumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Cholangiocarcinoma × durvalumab × Clear all
NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
5 enrolled 13 charts
Gastrointestinal

Cholangiocarcinoma

NCT04989218 2024-11-05

ICC

University of Alabama at Birmingham

Phase 1/2 Terminated
1 enrolled 11 charts
Gastrointestinal

Cholangiocarcinoma

NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
54 enrolled 14 charts
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡